BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
about
Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathwayKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsBCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cellsChanges in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells.The research on the immuno-modulatory defect of mesenchymal stem cell from Chronic Myeloid Leukemia patients.Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML.The biology of chronic myelogenous leukemia:mouse models and cell adhesion.Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.Molecular biological characteristics of the recruitment of hematopoietic stem cells from bone marrow niche in chronic myeloid leukemia.Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.MIP-1α/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia.Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia.Role of gene-expression profiling in chronic myeloid leukemia.Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.Genetic mechanisms of chronic myeloid leukemia blastic transformation.Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.Toward a general evolutionary theory of oncogenesis.Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it.Imatinib restores expression of CD62L in BCR-ABL-positive cells.Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
P2860
Q24676463-C3ACD822-625A-4D67-BC28-9E8CC56BF71AQ26849792-CB72749D-3C50-4444-BDBD-722C23B466ADQ28304582-3D299252-3A4D-44FA-ACC3-FB1285A73E84Q33689672-AE1C6548-1467-44D2-8640-A1694384DF84Q34984116-1A9868F4-ED16-4326-8710-85D90A3F5A41Q35022530-8E580B2B-7418-4FD3-8765-8C36FDDB51AFQ35022536-9B169510-4B60-4AA9-83AA-973714976A18Q35242120-4A668A10-5069-4288-8111-7F62F0E3E03DQ35802231-166E9E79-722B-48A8-8C7A-2BCDC9C98B85Q36161397-495F1288-71B0-4FFA-8054-C30E3F279594Q36286872-8CAE55FB-66DF-4A0B-9271-8859B5AC817CQ36375170-EA726836-00AE-4A43-B0A0-F3940BBE2488Q36485676-E7D74E4F-58EE-4601-A1EE-1E9D825ECEBAQ36599294-69407274-1C0C-4728-A66C-96AE2BC35A51Q36720075-21FE50C1-5B00-4DD0-A77A-639549F7834AQ37178213-32C31D54-6644-417F-A53F-79AE593E722BQ37322180-BCD62DFC-006C-4025-BCDA-7F9495756FC6Q37609692-6E8C065D-FCD2-4BC8-A9C3-1A4124296DA9Q37810111-D2266558-73B8-44BF-98B9-5176521DD6EDQ37836926-D1E7ECC7-8B44-42E3-891F-A3113AB6457BQ37983490-E90032BA-5166-4EBF-8F64-3B7BC99208BFQ38817737-0CD40F16-F59C-4165-97BF-E1F1A0B553C7Q39541093-1A5F2C33-3C9F-4D41-8DBA-3DDFB5C3D19EQ40039722-75A52045-D75C-4410-B384-786A2FC16D2FQ40314843-3A971F05-C68A-4649-B1E5-A68192DD3540Q41876296-2A6031B6-E30C-4DFC-B257-2C073C1FED42Q43932228-AF6C8647-3942-42D0-A72A-64AB77807E50Q44417197-D7CAE72E-9B0C-442B-8C47-44BF46FA914DQ52658167-26BE60FA-ED77-47A3-A578-0560D44EAB24Q53559086-4CD4BD69-6A80-4D2E-BDA0-40ADCC34D954Q58010946-9E5B0040-8AD1-4D97-A55C-1312A6F49EE2
P2860
BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
@en
type
label
BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
@en
prefLabel
BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
@en
P2093
P1433
P1476
BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
@en
P2093
Daniel Hammer
David Boettiger
Kevin Forsythe
Warren S Pear
P304
P356
10.1182/BLOOD.V99.11.4122
P407
P577
2002-06-01T00:00:00Z